| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
31,884 |
27,852 |
$3.88M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
24,652 |
21,163 |
$2.88M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14,060 |
12,641 |
$1.35M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
685 |
549 |
$1.27M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
9,531 |
8,542 |
$1.23M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,722 |
7,226 |
$802K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
10,170 |
8,778 |
$729K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,817 |
1,561 |
$656K |
| 71045 |
Radiologic examination, chest; single view |
5,724 |
4,835 |
$650K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,236 |
6,833 |
$490K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
8,914 |
7,925 |
$419K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,823 |
1,678 |
$229K |
| 62323 |
|
272 |
211 |
$226K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
6,794 |
5,960 |
$205K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
166 |
131 |
$184K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,484 |
2,931 |
$180K |
| 71046 |
Radiologic examination, chest; 2 views |
1,995 |
1,682 |
$161K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
4,206 |
3,656 |
$156K |
| 80053 |
Comprehensive metabolic panel |
26,151 |
22,086 |
$140K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
69 |
60 |
$138K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,566 |
1,462 |
$129K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
30,254 |
24,970 |
$124K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,304 |
327 |
$113K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
5,593 |
4,644 |
$104K |
| 27096 |
|
613 |
494 |
$104K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,092 |
1,897 |
$96K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
606 |
561 |
$95K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
329 |
185 |
$92K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
2,486 |
2,272 |
$82K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
527 |
185 |
$82K |
| 70450 |
Computed tomography, head or brain; without contrast material |
917 |
756 |
$80K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
3,087 |
2,573 |
$68K |
| 36415 |
Collection of venous blood by venipuncture |
23,306 |
19,587 |
$47K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
480 |
130 |
$47K |
| 84484 |
|
5,289 |
4,166 |
$39K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
169 |
144 |
$39K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,021 |
772 |
$38K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
221 |
200 |
$36K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
17 |
16 |
$34K |
| 71250 |
|
214 |
172 |
$23K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
393 |
362 |
$22K |
| 84703 |
|
4,894 |
4,256 |
$22K |
| 83690 |
|
7,216 |
6,231 |
$21K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,933 |
1,739 |
$17K |
| 85027 |
|
4,360 |
3,828 |
$16K |
| 87430 |
|
2,223 |
1,966 |
$15K |
| 86762 |
|
1,356 |
1,247 |
$15K |
| 76830 |
Ultrasound, transvaginal |
84 |
80 |
$15K |
| 81001 |
|
8,021 |
6,931 |
$13K |
| 76536 |
|
136 |
106 |
$13K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
689 |
632 |
$13K |
| 80305 |
|
2,382 |
2,120 |
$11K |
| 87088 |
|
1,931 |
1,775 |
$11K |
| 86803 |
|
971 |
895 |
$10K |
| 87631 |
|
100 |
93 |
$10K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
200 |
172 |
$9K |
| 87340 |
|
1,339 |
1,233 |
$8K |
| 20610 |
|
54 |
38 |
$7K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
12 |
12 |
$7K |
| 83655 |
|
579 |
536 |
$7K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
441 |
200 |
$7K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
13 |
13 |
$6K |
| 86850 |
|
1,344 |
1,235 |
$6K |
| 86703 |
|
615 |
570 |
$6K |
| 84439 |
|
990 |
902 |
$5K |
| 84145 |
|
439 |
358 |
$5K |
| 87486 |
|
221 |
200 |
$4K |
| 87581 |
|
221 |
200 |
$4K |
| 86592 |
|
1,370 |
1,258 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
73 |
66 |
$4K |
| 80320 |
|
72 |
66 |
$4K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
289 |
271 |
$4K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
834 |
666 |
$3K |
| 86901 |
|
1,361 |
1,248 |
$3K |
| 86900 |
|
1,361 |
1,248 |
$3K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
14 |
13 |
$3K |
| 81003 |
|
2,417 |
2,112 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
292 |
268 |
$3K |
| 83735 |
|
521 |
471 |
$2K |
| 82150 |
|
1,169 |
922 |
$2K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
304 |
239 |
$2K |
| 59050 |
|
22 |
13 |
$1K |
| 87040 |
|
268 |
179 |
$1K |
| 83880 |
|
118 |
93 |
$1K |
| J3490 |
Unclassified drugs |
736 |
525 |
$1K |
| 80069 |
|
322 |
276 |
$911.02 |
| 86140 |
|
327 |
296 |
$878.78 |
| 72120 |
|
17 |
14 |
$789.00 |
| 80061 |
Lipid panel |
98 |
87 |
$747.72 |
| 72050 |
|
12 |
12 |
$722.97 |
| 83970 |
|
81 |
67 |
$671.17 |
| 99215 |
Prolong outpt/office vis |
20 |
19 |
$612.00 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
29 |
25 |
$601.86 |
| 82533 |
|
55 |
41 |
$598.95 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
191 |
153 |
$554.74 |
| 82728 |
|
39 |
38 |
$493.62 |
| 85730 |
|
124 |
112 |
$421.89 |
| 85014 |
|
177 |
169 |
$408.67 |
| 85018 |
|
177 |
169 |
$408.67 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
16 |
12 |
$408.24 |
| 90837 |
Psychotherapy, 53 minutes with patient |
21 |
12 |
$354.15 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
49 |
27 |
$344.04 |
| 87150 |
|
14 |
13 |
$326.34 |
| 85610 |
|
160 |
137 |
$322.57 |
| 83550 |
|
39 |
38 |
$317.22 |
| 82803 |
|
35 |
24 |
$306.15 |
| 96376 |
|
72 |
60 |
$295.62 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
15 |
13 |
$264.60 |
| 83540 |
|
39 |
38 |
$235.32 |
| 82950 |
|
64 |
61 |
$168.55 |
| 82375 |
|
35 |
24 |
$160.16 |
| 81025 |
|
29 |
26 |
$148.95 |
| 85379 |
|
35 |
29 |
$134.34 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
35 |
32 |
$97.10 |
| 83605 |
|
14 |
12 |
$92.57 |
| 85652 |
|
55 |
50 |
$83.70 |
| 84702 |
|
15 |
13 |
$82.98 |
| 83615 |
|
13 |
12 |
$54.36 |
| 82040 |
|
14 |
12 |
$49.11 |
| 82947 |
|
21 |
20 |
$48.43 |
| 82570 |
|
15 |
12 |
$30.44 |
| 82043 |
|
15 |
12 |
$27.18 |
| 87186 |
|
14 |
12 |
$25.95 |
| 87077 |
|
14 |
12 |
$24.24 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
164 |
122 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
210 |
125 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
126 |
73 |
$0.00 |
| 94729 |
|
15 |
12 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
246 |
143 |
$0.00 |
| 94726 |
|
15 |
12 |
$0.00 |
| 77003 |
|
23 |
13 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
42 |
16 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
113 |
73 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
46 |
30 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
140 |
91 |
$0.00 |
| 88304 |
|
131 |
112 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
13 |
12 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
38 |
19 |
$0.00 |